CD19 and acute myeloid leukemia: While CAR T-cell therapy shows a high efficacy when the specific antigens on target cells are clearly identified as B-cell malignancies targeting CD19 and CD20 [113,114,115,116], the development of CAR T-cell therapy in AML may be a challenge because AML cells do not have a specific antigen.